OrbiMed Genesis GP LLC bought $2.0M of MBX Biosciences (MBX)

Executed Feb 14 2025, disclosed Feb 19 2025, 5 days later.

Value, as filed

$2.0M

190,672 sh across 4 lots

Executed

Feb 14 2025

the trade date, as filed

Disclosed

Feb 19 2025

5 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

-22.4%

-2.0% from execution

Over the 21 trading sessions from the disclosed entry session (Feb 19 2025), the stock returned -22.4% (delay-adjusted); from the execution session (Feb 14 2025), -2.0%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

OL OrbiMed Genesis GP LLC Director profile →

OrbiMed Genesis GP LLC (Director) filed 2 Form 4 reports as a reporting entity in the past 24 months (2 purchases, 0 sales), most often in Edgewise Therapeutics, Inc. (EWTX). Across 2 priced purchase filings, the average 21-session return was +5.7% from execution and +4.1% from disclosure (delay-adjusted; derived). The largest single filing was $10.0M of EWTX (496,771 sh across 2 lots, as filed), executed Apr 3 2025.

The name

MBX MBX MBX · 8 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→